Joshi J. Alumkal, M.D.
- Email:
- click here
- Office:
- 503 494-6594
Assistant Professor of Medicine
Background
Dr. Alumkal's research interest is cancer epigenetics, the study of heritable and potentially reversible changes in gene expression in cancer. His laboratory studies key chromatin modifying enzymes in cancer with an eye towards: 1) elucidating their function and role in transformation and disease progression and 2) targeting them with pharmacological agents in order to improve our ability to prevent and treat men with prostate cancer. Finally, his laboratory also focuses on the identification of biomarkers associated with prostate cancer development or aggressiveness.
Selected Publications
"Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone,"
"Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers,"
"C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results,"
"A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer,"
"A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma,"
